New Directions in Affective DisordersBernard Lerer, Samuel Gershon Springer Science & Business Media, 06.12.2012 - 732 Seiten This book is presented as a 1989 update on the task set by Robert Burton in his "Anatomy ofMelancholy," published in 1621. Burton's treatise addressed ques tions regarding depression which are still highly relevant today: ." . . What is it, with all the kinds, causes, symptoms, prognostickes and several cures ofit. . . . " These remain the core issues in affective disorders notwithstanding the remarkable progress that has been made in addressing them. New Directions in Affective Disorders sets out to provide an overviewofwhat has been achieved with particular emphasison developing trends and novel initiatives in bothfundamental research and treatment. The overriding objective of the book is to integrate significant contributions from basic and clinical science into a comprehensive format which will be of value to both clinicians and researchers. Intensive interest in affective illness isan inevitableconsequenceofthe frequency with which these disorders occur. Depression is the most common psychiatric condition, affecting as many as 50%ofpeople in Western countries at some time in their lives. National Institute ofMental Health Statistics estimate that 15% of adults between 18 and 74 years ofage may be suffering from serious depressive disorders in any given year. Depression is a serious condition with a high mortality. A suicide rate ofapproximately 20,000 deaths per year as a result of this illness is almost certainly a conservative estimate." |
Inhalt
Revelations About Major | 9 |
Past and Future | 17 |
BAdrenergic Agonists | 29 |
Serotonergic Aspects of Agonistic Behavior | 40 |
Neuropeptides and Affective Disorders | 49 |
Chronobiological Dysregulation of the Noradrenergic System | 52 |
Postmortem Investigation of Serotonergic and Peptidergic | 60 |
Impact of the Cholinergic System on the HypothalamicPituitary | 71 |
Psychiatric Disorders in Children of Depressed Parents | 356 |
Association of Somatic Disease with Affective Disorders | 367 |
Excess Mortality in Late Life Depression | 373 |
Psychosocial Perspectives | 382 |
MEIR STEINER | 393 |
EpinephrineInduced Anxiety and Regional Cerebral Blood Flow | 399 |
Caffeine Model of Panic | 410 |
Heterogeneity and Coexistence in DSMIIIR Obsessive | 421 |
Differential Effects of Physostigmine in Alcoholics Alcoholics with | 79 |
SerotoninNorepinephrineSteroid Receptor Link in Brain and | 85 |
LightDarkRelated Changes in the Serotonin Uptake Molecular | 93 |
GABAB Receptors and Antidepressant Drugs | 100 |
Nicotinic Effects of Antidepressants | 109 |
Modulation of the BenzodiazepineGABA Receptor Chloride | 118 |
Comparison of the Effects of Lithium and Antidepressant Drugs | 126 |
Phosphatidylinositol Metabolism with Theories Based | 134 |
Do They Act | 142 |
Selective Localization and Selective Inhibition of Monoamine | 151 |
Pharmacology of Monoamine Oxidase Inhibitors | 161 |
Neurochemical Profile of the Antidepressant Moclobemide | 168 |
Power of Genetic Linkage Studies for Heterogeneous Disorders | 177 |
MIRON BARON | 188 |
Segregation Analysis in Families of Affective Patients Subdivided | 196 |
α2Adrenoceptors and Associated Functional Responses | 209 |
High Affinity Imipramine Binding and Serotonin Uptake | 217 |
EEG Sleep Changes in Recurrent Depression | 225 |
What Is Normal | 239 |
Pathophysiology of the LimbicHypothalamicPituitary | 253 |
Preclinical and Clinical Investigations of CorticotropinReleasing | 262 |
TRH Stimulation Test in Psychiatry | 272 |
Neuroendocrine Factors in Antidepressant Drug Therapy | 280 |
Antidepressant Drugs | 284 |
Endocrinological Diseases Mimicking Affective Disorders | 292 |
Epidemiology and Psychosocial Risk Factors for Suicide | 301 |
Suicidal Behavior Among Children and Adolescents | 308 |
Neurotransmitters and Neurotransmitter Receptors in Depressed | 317 |
Comparing | 326 |
New Hypotheses of the Pharmacotherapy of Childhood | 340 |
Good Results with the Dexamethasone Suppression Test | 347 |
Use of Antiandrogens in the Treatment of Obsessive Compulsive | 438 |
Psychobiology of the Trauma Response | 443 |
From CSR to PTSD | 451 |
How Real Is the Relation? | 469 |
Neuroendocrine Findings in Depression Anorexia Nervosa | 475 |
Psychodynamic Reflections on Anorexia Nervosa | 484 |
Six Hypotheses | 490 |
Neuroendocrinology of Schizoaffective Disorders | 501 |
MARIO MAJ | 505 |
Pharmacotherapy and the Overlap Between Affective and Other | 515 |
Diagnostic Dimensions of the Newcastle Scales and the Response | 525 |
Acute and Prophylactic Properties of Carbamazepine in Bipolar | 535 |
Action of Carbamazepine Suspension in Acute Manic Syndromes | 545 |
Plasma Levels of Carbamazepine in Affective Disorder | 553 |
Patient Characteristics and Factors Associated with Chronic | 561 |
Clinical Indicators in Resistant Depressions | 573 |
Management of Resistant Major Depression | 582 |
Clinical Features DST and Response to Placebo | 596 |
Review of Methods | 605 |
Relation Between Plasma Antidepressant Concentrations | 611 |
Disposition and Effects of E10Hydroxynortriptyline | 620 |
Overdosage of Antidepressants | 631 |
GABA Theory of Depression and Antidepressant Drug Action | 651 |
Antidepressant Activity of Progabide and Fengabine | 660 |
A Controlled Study | 669 |
WEINER AND C E COFFEY | 677 |
Rising Trends and Current Policy | 685 |
Methodological Issues | 692 |
Current Status | 703 |
| 710 | |
Andere Ausgaben - Alle anzeigen
New Directions in Affective Disorders Dr Bernard Lerer,Samuel Gershon, M.D. Keine Leseprobe verfügbar - 1989 |
Häufige Begriffe und Wortgruppen
5-HT receptors abnormal action activity adenylate cyclase affective disorders affective illness affinity agonist amine amitriptyline antidepressant drugs antidepressant treatment anxiety Arch Gen Psychiatry associated behavioral benzodiazepine binding sites Biochem Biol Psychiatry biological blood Bmax carbamazepine cells cerebral cortex cholinergic chronic circadian clenbuterol Clin clinical clomipramine concentrations correlation cortisol decrease Department of Psychiatry depressed patients depressive illness desipramine dexamethasone disease dopamine dose effect of lithium endogenous factors function GABA GABAB genetic H]imipramine binding hormone human imipramine increased inhibition inhibitors linkage mania manic MAO-A MAO-B marker mechanisms Medical membranes metabolism metabolites mg/kg MHPG moclobemide monoamine oxidase monoamine oxidase inhibitors Neurochem neurons neurotransmitter nicotine noradrenergic norepinephrine panic peptide PH.D Pharmacol pharmacological placebo platelet protein Psychiatry rat brain receptor reported Research response schizoaffective serotonergic serotonin significant significantly specific ẞ-adrenoceptors studies suicide symptoms syndrome therapeutic therapy tricyclic antidepressants tyramine uptake vivo
